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ABSTRACT: Inorganic arsenic (iAs) is an environmental toxi-
cant currently poisoning millions of people worldwide, and
chronically exposed individuals are susceptible to arsenicosis
or arsenic poisoning. Using a state-of-the-art technique to map
the methylomes of our study subjects, we identiﬁed a large
interactomeofhypermethylatedgenesthatareenrichedfortheir
involvement in arsenic-associated diseases, such as cancer, heart
disease, and diabetes. Notably, we have uncovered an arsenic-
induced tumor suppressorome, a complex of 17 tumor suppres-
sors known to be silenced in human cancers. This ﬁnding represents a pivotal clue in unraveling a possible epigenetic mode of
arsenic-induced disease.
I
norganic arsenic (iAs) is an environmental toxicant currently
poisoning tens of millions of people worldwide. Individuals
chronically exposed to iAs are susceptible to arsenicosis or
chronic arsenic poisoning. Heavily suﬀering areas such as West
BengalandBangladeshsawariseinincidentsofarsenicosiswhen
government oﬃcials and international aid agencies, in the hopes
ofmitigatingwaterbornediseases,introducedtubewellsfedfrom
arsenic-contaminated aquifers.
1 Other regions, such as Mexico,
are aﬀected by both naturally occurring arsenic as well as anthro-
pogenic sources such as smelters and ore mining operations.
Chronic exposure to iAs is associated with the development of
variousdiseasesincludingheartdisease,diabetes,andcancer,and
exposed individuals often present with hallmark skin lesions.
2
Premalignantskinlesionsmayindicate increasedrisk forarsenic-
related cancer.
3 While the precise mode of action in arsenic-
induced disease is unknown, one of the proposed mechanisms is
altered gene regulation via epigenetic modes of action such as
DNA methylation.
4 Supporting this is the ﬁnding that early life
exposurecanresultinlong-termhealthconsequences,
5,6suggest-
ing that there are heritable changes to the genome.
Previous studies highlight the association of arsenicosis with
altered gene expression patterns in humans displaying the hall-
mark skin lesions.
7 Moreover, gene-speciﬁc analyses suggest
the role of altered DNA methylation at target sites such as
tumor protein p53 (p53), cyclin-dependent kinase inhibitor 2A
(CDKN2A/p16), and Ras association (RalGDS/AF-6) domain
family member 1 (RASSF1A).
8,9 However, it remains to be
shown whether multiple genes and pathways are aﬀected by
epigenetic processes in individuals with signs of arsenicosis.
Therefore, we set out to identify diﬀerentially methylated geno-
micregionsassociatedwitharsenicosisinhumansfromZimapan,
Hidalgo State, Mexico who were exposed to varying levels of iAs
via their drinking water as assessed by urinary arsenic (Support-
ing Information, Table 1).
To our knowledge, this is the ﬁrst study to examine genome-
wide site-speciﬁc DNA methylation alterations due to arsenic-
induced toxicity in a population with ongoing exposure. Periph-
eral blood lymphocyte DNA of 16 of the individuals, half with
established elevated levels of iAs exposure and showing signs of
arsenicosis (skin lesions), was analyzed using a methylated CpG
island recovery (MIRA)-chip assay. In addition to the diﬀerence
inskinlesionstatus,thetwogroupsshoweddiﬀerentlevelsofiAs
exposureasassessedinurine(p<0.001).CpG-methylatedDNA
wasisolatedusingamethylbindingdomainproteincomplexand
hybridizedtoAﬀymetrix HumanPromoter arrays,assessing over
4.6 million sites tiled through human promoter regions. Our
analysis enabled a comprehensive examination of DNA methyla-
tion levels within CpG islands for over 14,000 genes.
We employed a comparative analytical approach to identify
diﬀerentially methylated CpG islands and found 183 genes with
diﬀerential patterns, of which 182 were hypermethylated in
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individuals with signs of arsenicosis (Figure 1). Speciﬁcally, the
identiﬁed genes showed a statistically signiﬁcant (false discovery
rate (FDR) q-value <0.05) diﬀerence in average DNA methyla-
tion for each CpG island. This assay allowed for interrogation of
one the three genes previously identiﬁed as being hypermethy-
lated in individuals with signs of arsenicosis, e.g., p16. While the
fold change of p16 did not meet the statistical threshold for this
study, here we also observed increased promoter methylation in
individuals with signs of arsenicosis (fold change of 1.24).
Using a systems level approach, the 183 genes were analyzed
for known molecular interactions, and a large interactome of
hypermethylated genes was identiﬁed (Figure 2A). These are
enriched for their involvement in cancer-associated pathways
mediated by genes such as p53 (Figure 2B). Interestingly, we
found that many of the proteins encoded by genes with diﬀer-
entially methylated CpG islands are known players in arsenic-
associated disease, such as heart disease, diabetes, and cancer
(Supporting Information, Table 5).
Notably, we have also identiﬁed an arsenic-methylated tumor
suppressorome (Figure 2C), a pivotal clue in unravelling a
possible epigenetic mode of arsenic-induced disease. The tumor
suppressorome is a complex of 17 known or putative tumor
suppressors silenced in human cancers. It comprises the follow-
ing hypermethylated genes: C11orf70 (chromosome 11 open
reading frame 70), CENPE (centromere protein E, 312 kDa),
EEF1E1 (eukaryotic translation elongation factor 1 epsilon 1,
alsoknownasp18), ENDOG (endonucleaseG),FOXF1 (forkhead
boxF1),HOXB5(homeoboxB5),HOXB9(homeoboxB9),hsa-
mir-126 (human microRNA 126), MMP15 (matrix metallopep-
tidase 15 (membrane inserted)), MSX1 (msh homeobox 1, also
knownasHOX7),POLD4 (polymerase(DNA-directed),delta-4,
also known as p12), PRDM2 (PR domain containing 2, with
ZNF domain, also known as RIZ), RNF20 (ring ﬁnger protein
20), SMARCD2 (SWI/SNF related, matrix associated, actin
dependent regulator of chromatin, subfamily d, member 2),
SUFU (suppressor of fused homologue (Drosophila)), TBR1
(T-box, brain, 1), and TSC22D3 (TSC22 domain family,
member 3).
Among the members of the tumor suppressorome, of partic-
ular interest are those with known associations to arsenic-
induceddiseasessuchascancerofthebladder,kidney,lung,liver,
and prostate, as well as cardiovascular disease and diabetes
mellitus (Figure 2C, Supporting Information, Table 5). Interest-
ingly, the expression levels of speciﬁc members of the tumor
suppressorome have previously been shown to be altered via iAs
exposure. For example, iAs exposure in vitro results in the
downregulation of both MSX1
10 and CENPE.
11 In this study,
we ﬁnd that the CpG islands within the promoter regions of the
identiﬁed genes are hypermethylated in individuals with skin
lesions. As mentioned, DNA hypermethylation of the promoter
regions of three genes has been reported in arsenic-induced
disease.
8,9 Notably,the results from our studyvastly increase this
list of gene targets. Examination of these gene targets would be
the next step in understanding how epigenetic changes regulate
gene expression and, subsequently, cause dysregulation leading
to disease.
In this study we have analyzed epigenetic changes in the
peripheral blood lymphocyte DNA from iAs exposed and
diseasedindividualsanddonotdirectlymeasurealterationsintarget
organs. Recent studies support the utilization of lymphocyte
Figure 1. Arsenicosis-associated patterns of DNA methylation. The
heat map illustrates the average DNA methylation levels in promoter
regions of 183 genes. Data are z-score normalized for each gene. Red
represents a relative increase in CpG island methylation level, and blue
represents a relative decrease in methylation level.
Figure 2. Epigenetically modiﬁed iAs-induced networks. (A) Large interacting network of hypermethylated genes. (B) Tumor protein p53 (tp53)-
associated network. (C) The iAs-induced tumor suppressorome. P-values are shown in the top right corners of each network. Networks are displayed
with symbols representing products of hypermethylated genes (red symbols) or the proteins associated with these genes (clear symbols).167 dx.doi.org/10.1021/tx1004419 |Chem. Res. Toxicol. 2011, 24, 165–167
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DNA to detect genomic and epigenetic biomarkers of organ-
speciﬁc disease.
12,13 In future research, it will be possible to
compare the epigenetic alterations of the tumor suppressorome
from tissue samples of arsenic-exposed individuals.
In conclusion, these results demonstrate that a large number
of genes are epigenetically modiﬁed in the lymphocyte DNA of
individualsexposedtoiAswithrelatedarsenicosis.Itislikelythat
the pathways we have identiﬁed here are inﬂuenced at the
transcriptional level resulting in the repression of their activity
in exposed individuals. Our ﬁndings demonstrate the signiﬁcant
eﬀects of iAs on the epigenome. The identiﬁed methylation sites
and diﬀerential DNA methylation patterns may serve as bio-
markers of adverse health eﬀects associated with iAs exposure.
Throughtheidentiﬁcationofdiﬀerentialpatternsofmethylation,
we hope to detail arsenic eﬀects in humans in order to under-
stand arsenic-induced disease and to identify potential methods
for disease prevention.
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